Oxford Immunotec signed distributor agreement with RIKEN Genesis for T-SPOT Discovery SARS-CoV-2 Kit in Japan
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
BD to invest $12 billion in pre-fillable syringe manufacturing capacity over next four years
On Dec. 2, 2020, BD (Becton, Dickinson) announced plans to invest approximately $1.2 billion over a 4-year period…
Biotechnology | COVID-19 | Therapeutics | WHO
Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19
On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, the City of Hope reported that its investigational vaccine produced strong protective immunity against…
Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
Lonza expanded development and manufacturing aapabilities at Bend facility
On Nov. 30, 2020, Lonza announced $10 million investment in its Bend, Oregon facility. Originally known as Bend…
RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19
On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure…
Todos Medical completed installation of lab automation equipment at Wisconsin lab for COVID-19 PCR testing
On Nov. 24, 2020, Todos Medical announced that it has completed the installation of Tecan’ laboratory automated equipment…
CytoDyn reached enrollment target of 293 patients for 2nd DSMC interim analysis of phase 3 COVID-19 trial
On Nov. 23, 2020, CytoDyn announced it had reached enrollment of 293 patients in its Phase 3 trial…
Study of ‘exceptional responders’ yields clues to cancer and potential treatments
On Nov. 19, 2020, in a comprehensive analysis of patients with cancer who had exceptional responses to therapy,…
Viruses shown to evolve as a result of different immune responses in different ethnic populations
On Nov. 19, 2020, University of Oxford researchers announced that research into the HIV-1 virus had shed light…
Novartis secured exclusive rights for potential acute respiratory distress syndrome cell therapy
On Nov. 19, 2020, Novartis announced that it had entered into an exclusive worldwide license and collaboration agreement…
Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidate
On Nov. 19, 2020, Medigen Vaccine Biologics announced that preclinical results of their COVID-19 vaccine candidate had been…
Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
Baricitinib received Emergency Use Authorization from FDA for treatment of hospitalized patients with COVID-19
On Nov. 19, 2020, Eli Lilly and Incyte announced that the FDA had issued an Emergency Use Authorization…
Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
RedHill’s second COVID-19 candidate cleared by FDA for phase 2/3 Study in symptomatic COVID-19 disease
On Nov. 17, 2020, RedHill Biopharma announced that the U.S. Food and Drug Administration (FDA) had cleared the…
Mayo Clinic reported 900 employees contracted COVID-19 from local community
On Nov. 17, 2020, the Mayo Clinic reported that more than 900 employees had contracted COVID-19 in the…
bioMerieux announced CE marking of ARGENE SARS-CoV-2 diagnostic test to include saliva specimens
On Nov. 16, 2020, bioMerieux announced the expansion of its ARGENE range for the detection of SARS-CoV-2. As…
RedHill completed enrollment for COVID-19 US phase 2 study with opaganib
On Nov. 16, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 16, 2020, Moderna announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase…
FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBC
On Nov. 13, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s…
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
On Nov. 13, 2020, NeuroRx and Relief Therapeutics announced that to-date, 150 patients (out of a targeted enrollment…
Agilent received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer
On Nov. 13, 2020, Agilent Technologies announced it had received U.S. Food and Drug Administration (FDA) approval for…
Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
Respiratory failure in COVID-19 usually not driven by cytokine storm
On Nov. 13, 2020, a study from Washington University School of Medicine in St. Louis and St. Jude…
Wren Laboratories launched saliva-based PCR COVID-19 test
On Nov. 12, 2020, Wren Laboratories announced that it had been granted an emergency use authorization by the…
Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
DSMB analysis recommended continuance of P3 COVID-19 ARDS trial
On Nov. 11, 2020, Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with…